TET3 Inhibits Type I IFN Production Independent of DNA Demethylation.

[1]  L. Hui,et al.  STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. , 2015, The Journal of clinical investigation.

[2]  Cheng Luo,et al.  Structural insight into substrate preference for TET-mediated oxidation , 2015, Nature.

[3]  Xia Li,et al.  Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 , 2015, Nature.

[4]  E. Zandi,et al.  Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis. , 2015, Immunity.

[5]  A. Ferguson-Smith,et al.  CRISPR-Cas9-Mediated Genetic Screening in Mice with Haploid Embryonic Stem Cells Carrying a Guide RNA Library. , 2015, Cell stem cell.

[6]  Mingzhou Chen,et al.  Casein Kinase II Controls TBK1/IRF3 Activation in IFN Response against Viral Infection , 2015, The Journal of Immunology.

[7]  C. Rudd,et al.  ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy , 2015, EMBO molecular medicine.

[8]  R. Jaenisch,et al.  TET1 is a tumor suppressor of hematopoietic malignancy , 2015, Nature Immunology.

[9]  D. Schübeler.  Function and information content of DNA methylation , 2015, Nature.

[10]  E. Ballestar,et al.  Epigenetic control of myeloid cell differentiation, identity and function , 2014, Nature Reviews Immunology.

[11]  B. Wei,et al.  Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NF-κB signaling and protects against endotoxin shock. , 2014, Immunity.

[12]  W. Liu,et al.  Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. , 2014, Cell stem cell.

[13]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[14]  Lifang Jiang,et al.  miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6. , 2013, The Journal of infection.

[15]  P. Cartron,et al.  Identification of TET1 Partners That Control Its DNA-Demethylating Function. , 2013, Genes & cancer.

[16]  R. Schreiber,et al.  Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling , 2013, Science.

[17]  B. Aronow,et al.  Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection , 2013, Science.

[18]  Y. Shi,et al.  Tet family proteins and 5-hydroxymethylcytosine in development and disease , 2012, Development.

[19]  W. Reik,et al.  Uncovering the role of 5-hydroxymethylcytosine in the epigenome , 2011, Nature Reviews Genetics.

[20]  Z. Deng,et al.  The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes , 2011, Nature.

[21]  Yang Wang,et al.  Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA , 2011, Science.

[22]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[23]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[24]  J. Mellors,et al.  Inhibitors of Histone Deacetylases , 2011, The Journal of Biological Chemistry.

[25]  Juri Rappsilber,et al.  TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity , 2011, Nature.

[26]  Andrew Macdonald,et al.  Putting the brakes on the anti-viral response: negative regulators of type I interferon (IFN) production. , 2011, Microbes and infection.

[27]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[28]  G. Trinchieri,et al.  Type I interferon: friend or foe? , 2010, The Journal of experimental medicine.

[29]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[30]  Dimitris Thanos,et al.  The transcriptional code of human IFN-beta gene expression. , 2010, Biochimica et biophysica acta.

[31]  L. Rönnblom,et al.  Type I interferon and lupus , 2009, Current opinion in rheumatology.

[32]  Pin Wang,et al.  MicroRNA-146a Feedback Inhibits RIG-I-Dependent Type I IFN Production in Macrophages by Targeting TRAF6, IRAK1, and IRAK21 , 2009, The Journal of Immunology.

[33]  G. Comi.  Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. , 2009, Clinical therapeutics.

[34]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1 , 2009, Science.

[35]  A. Smahi,et al.  TLR3 Deficiency in Patients with Herpes Simplex Encephalitis , 2007, Science.

[36]  C. Horvath,et al.  Positive and Negative Regulation of the Innate Antiviral Response and Beta Interferon Gene Expression by Deacetylation , 2006, Molecular and Cellular Biology.

[37]  Stanley M Lemon,et al.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Unanue,et al.  Type I Interferon Sensitizes Lymphocytes to Apoptosis and Reduces Resistance to Listeria Infection , 2004, The Journal of experimental medicine.

[39]  Jiahuai Han,et al.  Identification of Lps2 as a key transducer of MyD88-independent TIR signalling , 2003, Nature.

[40]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[41]  J. Doly,et al.  Inhibition of Histone Deacetylation Induces Constitutive Derepression of the Beta Interferon Promoter and Confers Antiviral Activity , 2001, Journal of Virology.